Radically Simplify Your CGP and HRD Workflow With Industry-Leading Automation Using the AVENIO Tumor Tissue CGP Automated Kit

The new AVENIO Tumor Tissue CGP Automated Kit*, developed by Roche and Foundation Medicine, is a Research Use Only product for comprehensive genomic profiling of solid tumor specimens. It analyzes 335 genes, 4 alteration classes, and 4 genomic signatures. Featuring a panel aligned with FoundationOne® CDx panel design and robust bioinformatics from the FoundationOne® Analysis Platform, it includes a new pan-tumor HRD signature developed by Foundation Medicine. The kit offers fully automated library preparation and target enrichment with 24 hours of walk-away time via the AVENIO Edge, and approximately 3.5 hours of hands-on time from DNA extraction to results. The AVENIO Tumor Tissue CGP Automated Kit demonstrates robust performance and radically simplifies sequencing workflows through automation.
* Product in development. For Research Use Only.